[1]
Jacobs I,Bast RC Jr, The CA 125 tumour-associated antigen: a review of the literature. Human reproduction (Oxford, England). 1989 Jan; [PubMed PMID: 2651469]
[3]
Bast RC Jr,Klug TL,St John E,Jenison E,Niloff JM,Lazarus H,Berkowitz RS,Leavitt T,Griffiths CT,Parker L,Zurawski VR Jr,Knapp RC, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. The New England journal of medicine. 1983 Oct 13; [PubMed PMID: 6310399]
[4]
Bast RC Jr,Feeney M,Lazarus H,Nadler LM,Colvin RB,Knapp RC, Reactivity of a monoclonal antibody with human ovarian carcinoma. The Journal of clinical investigation. 1981 Nov; [PubMed PMID: 7028788]
[5]
Yin BW,Lloyd KO, Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. The Journal of biological chemistry. 2001 Jul 20; [PubMed PMID: 11369781]
[6]
Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstetrics and gynecology. 2016 Nov; [PubMed PMID: 27776072]
[7]
Kenemans P,Yedema CA,Bon GG,von Mensdorff-Pouilly S, CA 125 in gynecological pathology--a review. European journal of obstetrics, gynecology, and reproductive biology. 1993 Apr; [PubMed PMID: 8365505]
[8]
Grover S,Koh H,Weideman P,Quinn MA, The effect of the menstrual cycle on serum CA 125 levels: a population study. American journal of obstetrics and gynecology. 1992 Nov; [PubMed PMID: 1442994]
[9]
Seki K,Kikuchi Y,Uesato T,Kato K, Increased serum CA 125 levels during the first trimester of pregnancy. Acta obstetricia et gynecologica Scandinavica. 1986; [PubMed PMID: 3467532]
[10]
Kobayashi F,Sagawa N,Nakamura K,Nonogaki M,Ban C,Fujii S,Mori T, Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. American journal of obstetrics and gynecology. 1989 Mar; [PubMed PMID: 2929674]
[11]
Verheijen RH,von Mensdorff-Pouilly S,van Kamp GJ,Kenemans P, CA 125: fundamental and clinical aspects. Seminars in cancer biology. 1999 Apr; [PubMed PMID: 10202133]
[12]
Kui Wong N,Easton RL,Panico M,Sutton-Smith M,Morrison JC,Lattanzio FA,Morris HR,Clark GF,Dell A,Patankar MS, Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. The Journal of biological chemistry. 2003 Aug 1; [PubMed PMID: 12734200]
[13]
el Ouagari K,Teissié J,Benoist H, Glycophorin A protects K562 cells from natural killer cell attack. Role of oligosaccharides. The Journal of biological chemistry. 1995 Nov 10; [PubMed PMID: 7592944]
[14]
Yoshimura M,Ihara Y,Ohnishi A,Ijuhin N,Nishiura T,Kanakura Y,Matsuzawa Y,Taniguchi N, Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer research. 1996 Jan 15; [PubMed PMID: 8542600]
[15]
Sharma S, Tumor markers in clinical practice: General principles and guidelines. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical [PubMed PMID: 20668599]
[16]
Sturgeon CM,Hoffman BR,Chan DW,Ch'ng SL,Hammond E,Hayes DF,Liotta LA,Petricoin EF,Schmitt M,Semmes OJ,Söletormos G,van der Merwe E,Diamandis EP, National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clinical chemistry. 2008 Aug; [PubMed PMID: 18606634]
[17]
Meyer T,Rustin GJ, Role of tumour markers in monitoring epithelial ovarian cancer. British journal of cancer. 2000 May; [PubMed PMID: 10789720]
[18]
Kenemans P,van Kamp GJ,Oehr P,Verstraeten RA, Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clinical chemistry. 1993 Dec; [PubMed PMID: 8252723]
[19]
Eltabbakh GH,Gupta MK,Belinson JL,Kennedy AW,Webster K,Paraiso MF, Comparison between Centcor CA 125 and CA 125 II assays. European journal of gynaecological oncology. 1996; [PubMed PMID: 8971528]
[20]
Muto MG,Lepisto EM,Van den Abbeele AD,Knapp RC,Kassis AI, Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. American journal of obstetrics and gynecology. 1989 Nov; [PubMed PMID: 2686446]
[21]
Dodge JE,Covens AL,Lacchetti C,Elit LM,Le T,Devries-Aboud M,Fung-Kee-Fung M, Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecologic oncology. 2012 Jul; [PubMed PMID: 22484399]
[22]
Myers ER,Bastian LA,Havrilesky LJ,Kulasingam SL,Terplan MS,Cline KE,Gray RN,McCrory DC, Management of adnexal mass. Evidence report/technology assessment. 2006 Feb; [PubMed PMID: 17854238]
[23]
Prat J, Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2014 Jan; [PubMed PMID: 24219974]
[24]
ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstetrics and gynecology. 2002 Dec; [PubMed PMID: 12468197]
[25]
Buys SS,Partridge E,Black A,Johnson CC,Lamerato L,Isaacs C,Reding DJ,Greenlee RT,Yokochi LA,Kessel B,Crawford ED,Church TR,Andriole GL,Weissfeld JL,Fouad MN,Chia D,O'Brien B,Ragard LR,Clapp JD,Rathmell JM,Riley TL,Hartge P,Pinsky PF,Zhu CS,Izmirlian G,Kramer BS,Miller AB,Xu JL,Prorok PC,Gohagan JK,Berg CD, Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 8; [PubMed PMID: 21642681]
[26]
Mongia SK,Rawlins ML,Owen WE,Roberts WL, Performance characteristics of seven automated CA 125 assays. American journal of clinical pathology. 2006 Jun; [PubMed PMID: 16690492]
[27]
Vernooij F,Heintz P,Witteveen E,van der Graaf Y, The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecologic oncology. 2007 Jun; [PubMed PMID: 17433422]
[28]
Ganesan P,Kumar L,Hariprasad R,Gupta A,Dawar R,Vijayaraghavan M, Improving care in ovarian cancer: the role of a clinico-pathological meeting. The National medical journal of India. 2008 Sep-Oct; [PubMed PMID: 19320321]
[29]
Clarke L,Bailey C, Managing women with ovarian cancer: the role of the nurse. Nursing standard (Royal College of Nursing (Great Britain) : 1987). 2010 Oct 6-12; [PubMed PMID: 21133017]
[30]
Junor EJ,Hole DJ,Gillis CR, Management of ovarian cancer: referral to a multidisciplinary team matters. British journal of cancer. 1994 Aug; [PubMed PMID: 8054286]